View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Deutsche Pfandbriefbank AG: 4 directors

Four Directors at Deutsche Pfandbriefbank AG bought 32,013 shares at between 5.410EUR and 5.559EUR. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: To divest 87 stores in Romania. DEME Group: Preview – a busy first half year. Kendrion: Preview - 2Q similar to 1Q. Sif Group: Preview - quarterly jump in EBITDA close?

Thomas J. Schiessle
  • Thomas J. Schiessle

Weak economy delays "Profitability Restart" - 25 guidance correction -...

The Q2/25 KPIs show a deterioration in revenue and EBITDA margins - contrary to management and market expectations (revenue -6% YoY to €171.2m / margin: -4.08%; EPS €-0.25), but these are exaggerated due to phasing effects and reset savings. Revenue and margins in the "restart phase" starting Q3/25 are expected to expand. However, the necessary revival of customer demand in the pharma and biotech industry is still lacking (contractionary US R&D and industrial policy, hesitant investments). There...

Thomas J. Schiessle
  • Thomas J. Schiessle

Schwache Konjunktur verzögert „Profitability Restart“ - 25er Guidance-...

Die Q2/25-KPIs zeigen - entgegen der Management- und Markt-Erwartung - eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -6% YoY auf € 171,2 Mio./Marge: -4,08 %; EPS € -0,25), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Umsatz und Margen in der „Restart-Phase“ ab Q3/25 sollen ausgeweitet werden. Doch die dafür nötige wiederauflebende Kundennachfrage in Pharma- und Biotech-Industrie bleibt bis heute aus (kontraktive US-R&D- und Industriepolitik, zögerliche Inv...

Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/HQLA demand for covered bonds, PBB 2Q loss, digitalisation...

Covered bonds lose ground to Govies & SSAs in EU HQLA portfolios. Deutsche Pfandbriefbank earnings swing to a significant loss. ECB explores the effect of digitalisation on deposit outflows.

Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/HQLA demand for covered bonds, PBB 2Q loss, digitalisation...

Covered bonds lose ground to Govies & SSAs in EU HQLA portfolios. Deutsche Pfandbriefbank earnings swing to a significant loss. ECB explores the effect of digitalisation on deposit outflows.

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf
Damien Choplain ... (+3)
  • Damien Choplain
  • Maria Vara
  • Oscar Haffen Lamm

End of coverage

From 5th August 2025, we will no longer include the following companies in our coverage:EVOTECMEDIOSDBV Technologies

Steven Gould
  • Steven Gould
Steven Gould
  • Steven Gould
Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/UniCredit 2Q, crypto regulation, CRE and German cover pool...

UniCredit earnings a little sluggish, but capital remains strong; Financial associations ask to update crypto regulations; CRE exposure and German cover pools: a concern of the past?

Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/UniCredit 2Q, crypto regulation, CRE and German cover pool...

UniCredit earnings a little sluggish, but capital remains strong; Financial associations ask to update crypto regulations; CRE exposure and German cover pools: a concern of the past?

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Evotec - Another Warning – PT Cut to €5.40 (SELL, TP EUR5.40 [7], 9pgs...

Following yesterday's cut to sales guidance, we cut our PT to €5.40 and L-T revenues by 10-15%. We are 40% below consensus EBITDA in 2028 despite including significantly more cost savings. We show the base business is loss making this year & could just break even in 2026. We are most concerned about the reliance on single lumpy contracts. The SDZ milestones will mostly disappear by 2028 & the commercial revenues required to offset them imply biosimilar sales of €550m by 2030 for drugs that will ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Kinepolis: June 2025 Box office revenue/ attendance in US/Canada and France down. Utilities – Offshore Wind: Big Not So Beautiful Bill

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch